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Sungeun Chang, M.D., Mi-Woo Lee, M.D., Jee-Ho Choi, M.D., Kee-Chan Moon, M.D.
Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Background: Subcutaneous panniculitis-like T-cell lympho-
ma (SPTL) is a distinctive skin lymphoma characterized by 
neoplastic T-cell infiltration of the subcutaneous tissue, 
mimicking panniculitis. Objective: To describe the clinical 
and pathologic features of SPTL in Korean patients. Methods: 
Fourteen SPTL patients evaluated over 15 years were 
retrospectively reviewed. Results: The mean patient age was 
35 years (range: 7∼73 years), with male predominance 
(2.5:1). Most patients presented with either nodules or 
plaques, occurring most commonly on the trunk, with two 
patients (14%) having hemophagocytic syndrome. Histo-
pathologically, all patients showed infiltrates of small-to- 
medium pleomorphic cells mimicking panniculitis, with 
some also showing rimming, bean-bag cells, and fat necrosis. 
Most patients were positive for CD3 (14/14), CD8 (12/13), 
TIA-1 (9/9) and βf1 (5/5), but were negative for CD4 (11/12), 
CD20 (8/8), CD56 (14/14) and Epstein-Barr virus (8/8). Ten 
patients (71%) received chemotherapy and 2 (14%) died due 
to the disease, with an average survival time of 4 months. 
Survival analysis did not reveal any significant prognostic 
factors. Conclusion: This is the first series of patients with 
SPTL in Korea. Due to its indolent clinical course and 
relatively high survival rate, SPTL should be differentiated 
from cutaneous γ δ  T-cell lymphoma. (Ann Dermatol 23(3) 
329∼337, 2011)
-Keyword-
Subcutaneous panniculitis-like T-cell lymphoma
INTRODUCTION
Subcutaneous panniculitis-like T-cell lymphoma (SPTL) is 
a distinctive skin lymphoma characterized by neoplastic 
cytotoxic T cell infiltration of the subcutaneous tissue, 
mimicking panniculitis. Two subtypes have been describ-
ed, i.e., the SPTL of α β T-cell and γ δ T-cell origin, each 
of them showing a different phenotype and clinical 
course. T-cell receptor (TCR) α β lymphomas are usually 
CD4−, and CD56−, but CD8＋, and have an indolent 
course, whereas TCR γ δ lymphomas are usually CD4−, 
and CD8−, but CD56＋, are associated with a poor 
prognosis, and are often fatal due to the accompanying 
hemophagocytic syndrome
1. The recent World Health 
Organization (WHO)-European Organization for Research 
and Treatment of Cancer (EORTC) classification of primary 
cutaneous lymphomas, however, restricted the category of 
SPTL to lymphomas expressing the TCR α β phenotype, 
placing those expressing the TCRγ δ phenotype into a 
new provisional category of cutaneous γ δ  T-cell lympho-
ma
2. Few studies to date, however, have assessed patients 
with SPTL, as defined by the WHO-EORTC classification 
system. We therefore assessed the clinical and pathologic 
features of 14 Korean patients with SPTL, their response to 
treatment, and prognosis.
MATERIALS AND METHODS
Patient selection
Twenty-two patients with SPTL were evaluated in the DW Lee, et al
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Table 1. Clinical features of the 14 investigated patients with 
SPTL
Mean age, years (range)  35.1 (7∼73)
Duration, months     21.2
Sex (M:F)     2.5:1
  M a l e     1 0
  F e m a l e        4
Presenting skin lesions 
  Plaque  3/14 (21)
  Nodule 13/14 (93)
  Ulcer  0/14 (0)
  Cellulitis  2/14 (14)
  Swelling  2/14 (14)
Extent of cutaneous involvement 
  Solitary     0  (0) 
  Localized  2/14 (14)
  Multiple 12/14 (86)
Site
  Face  4/14 (29)
  Trunk 10/14 (71)
  Upper extremities  8/14 (57)
  Lower extremities  9/14 (64)
Extracutaneous lesions
  Lymphadenopathy  5/13 (39)
  Bone marrow involvement     0  (0)
  Splenomegaly  4/13 (31)
  Hepatomegaly 2/13 (15)
Initial treatment
  Chemotherapy  10/14 (71)
  Immunosuppressive therapy   3/14 (21)
  Radiotherapy     0 (0)
  Autologous stem cell transplantation     0 (0)
  Symptomatic therapy   1/14 (7)
Result initial treatment 
  Complete remission  4/14 (29)
  Partial remission  2/14 (14)
  No response  1/14 (7)
  Progressive disease  7/14 (50)
Status at last follow-up
  Dead  2/14 (14) 
  Alive with disease  9/14 (64)
  Alive without disease  3/14 (21)
Mean survivial, month
  D e a d      4
  Alive with disease     22.7
  Alive without disease     40
Clinical manifestations
  Hemophagocytic syndrome  2/14 (14)
  B-symptoms  9/13 (69)
  Increased LDH  9/13 (69)
  Decreased WBC counts  7/14 (50)
  Anemia  6/14 (43)
  Elevated LFT  7/14 (50)
Data are numbers (%) unless otherwise indicated. SPTL: 
subcutaneous panniculitis-like T-cell lymphoma, LDH: lactate 
dehydrogenase, LFT: lupus erythematosus profundus.
Dermatology Department of the Asan Medical Center, 
between January 1995 and September 2009. Eight patients 
were excluded owing to insufficient material or problems 
with the clinical data. The medical records of the 
remaining 14 patients were extensively reviewed, and 
patients’ age, sex, clinical presentation, treatments, res-
ponse to therapy and follow-up were recorded.
Histology and immunohistochemistry
Representative histopathologic sections and immunohisto-
chemical slides were reviewed by two dermatologists to 
identify the subcutaneous panniculitis-like T-cell lympho-
ma, according to the new WHO-EORTC classification. 
Additional staining was requested, if not previously 
performed. The antibodies used were directed against 
CD3 (polyclonal; Dako, Glostrup, Denmark), CD4 (1F6; 
Novocastra, Newcastle upon Tyne, UK), CD8 (C8/144B; 
Dako, Glostrup, Denmark), CD20 (L26; Dako, Glostrup, 
Denmark), CD30 (Ber-H2; Dako, Glostrup, Denmark), 
CD56 (123, C3; Zymed, South San Francisco, CA, USA), 
Granzyme B (GZB01; NeoMarkers, Fremont, CA, USA), 
TIA-1 (2G9; Dako, Glostrup, Denmark), and TCR-betaF1 
(8A3; Thermo Scientific, Woburn, MA, USA).
In situ hybridization (ISH) for the Epstein-Barr virus (EBV)
ISH for EBV was performed on skin samples from eight 
patients, plus positive and negative controls, using the 
Ventana Benchmark autostainer and the Epstein-Barr Virus 
Early RNA (EBER) kit (Ventana Medical Systems, Tucson, 
AZ, USA).
TCR gamma gene rearrangement
Polymerase chain reaction (PCR) analysis of the TCR 
gamma gene was performed on routinely fixed, paraffin- 
embedded, tissue specimens from eight patients, as 
described previously
3.
Survival and statistical analysis
The overall survival was calculated from the date of 
histologically confirmed diagnosis until death or last 
follow-up. Survival curves were estimated using the 
Kaplan-Meier method and compared using the log-rank 
test. All statistical analyses were performed using the 
Statistical Product and Services Solutions (SPSS) software, 
version 12.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Clinical manifestations (Tables 1 and 2)
The clinical features of the 14 patients (10 male and 4 
female) are summarized in Tables 1 and 2. The mean 
patient age was 35 years (range: 7∼73 years), and the 
mean duration of skin lesions prior to diagnosis was 21.2 
months.
All patients presented with multiple lesions, 10 with Subcutaneous Panniculitis-Like T-cell Lymphoma in Korea
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Fig. 1. Clinical findings in patients 
with subcutaneous panniculitis-like 
T-cell lymphoma. Shown are cha-
racteristic multiple erythematous 
indurated plaques and nodules on 
(a) the face of patient 16, (b) the 
trunk of patient 7, (c) the lower leg 
of patient 6, and (d) the upper 
extremities of patient 5.
lesions on the trunk (71%), 9 with lesions on the lower 
extremities (64%), 8 with lesions on the upper extremities 
(57%) and 4 with lesions on the face (29%). Thirteen 
patients (93%) presented predominantly with nodules, 3 
(21%) with plaque, and 2 (14% with swelling (Fig. 1); no 
lesion was accompanied by ulceration. Many patients 
showed evidence of extracutaneous manifestations at 
presentation. For example, of the 13 patients who 
underwent computed tomography (CT) scans, 4 (31%) had 
splenomegaly, including 2 (15%) with hepatomegaly, and 
5 (39%) had lymphadenopathy. No patient had bone 
marrow involvement, as confirmed by biopsy. Two 
patients (14%) developed the hemophagocytic syndrome, 
and 9 of 13 patients (69%) presented with B symptoms, 
including fever, night sweats, and/or weight loss. Seven 
patients (50%) showed decreased white blood cell counts 
and increased liver enzyme concentrations, and six (43%) 
had anemia. Increased lactate dehydrogenase (LDH) 
concentrations were detected in 9 of 13 patients (69%). 
However, staging procedures showed no evidence of 
lymphoma outside the skin in any of the investigated 14 
patients.
The clinical presentation of these patients included 3 with 
erythema nodosum, 2 with connective tissue disease, and 
one each with panniculitis, Sweet syndrome, hemophago-
cytic syndrome, and cellulitis.
Histologic findings (Table 3)
The biopsy specimens of all 14 patients showed dense 
infiltrates, in a lobular pattern, of atypical lymphocytes, Subcutaneous Panniculitis-Like T-cell Lymphoma in Korea
Vol. 23, No. 3, 2011 333
Fig. 2. Histopathologic findings in patients with subcutaneous panniculitis-like T-cell lymphoma. (a) Atypical lymphocyte infiltration 
in a lobular, panniculitis-like pattern (H&E, ×40). (b) Atypical lymphocytes rimming adipocytes (H&E, ×400). (c) Bean-bag cells (H&E,
×400). (d) Extensive necrosis (H&E, ×200).
Table 3. Histopathologic data of 14 patients with SPTL
No. Lobular 
panniculitis-like
Involvement of epidermis 
(E) or dermis (D) Rimming Karyorrhexis Fat 
necrosis Angio-centricity Features associated 
with LE Cytology
 1( ＋) Deep D (periadenxal) (＋)( ＋)( ＋)( ＋) (−)S - M
 2( ＋) Deep D (periadenxal) (＋)( ＋)( ＋)( −)( −)S - M  
 3( ＋)( −)( ＋)( ＋)( ＋)( −)( −)M
 4( ＋)( −)( ＋)( −)( ＋)( ＋)( −)S - M
 5( ＋)( −)( ＋)( ＋)( ＋)( ＋)( −)M
 6( ＋)( −)( ＋)( ＋)( ＋)( ＋) (−)M - L
 7( ＋) Deep D (periadenxal) (＋)( ＋)( ＋)( −) Vaculoar change (＋) M-L
 8( ＋) Deep D (perivascular) (＋)( ＋)( ＋)( ＋) Vaculoar change (＋), M
 Plasma cell (＋)
 9( ＋)( −)( ＋)( −)( ＋)( −)( −)M
10 (＋)( −)( ＋)( ＋)( −)( −)( −)S - M
11 (＋)( −)( ＋)( ＋)( ＋)( −) Plasma cell(＋) S-M
12 (＋)( −)( ＋)( ＋)( ＋)( −)( −)M
13 (＋)( −)( ＋)( ＋)( ＋)( −)( −)M
14 (＋) Deep D (Perivascular) (＋)( ＋)( ＋)( −)( −)S - M
SPTL: subcutaneous panniculitis-like T-cell lymphoma, S: small, M: medium, L: large, LE: lupus erythematosus.DW Lee, et al
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Fig. 3. Immunohistochemical analysis in patients with subcutaneous panniculitis-like T-cell lymphoma, showing that neoplastic cells 
in the subcutis were positive for (a) CD3, (b) CD8, (c) granzyme B, and (d) T-cell intracellular antigen-1 (all original magnification, 
×200).
Table 4. Immunohistochemical and molecular data of 14 patients
with SPTL
CD3 14/14 (100)
CD4  1/13 (8)
CD8 12/13 (92)
CD20   0/8 (0)
CD30   0/8 (0)
CD56  0/14 (0)
EBV   0/8 (0)
TIA-1   9/9 (100)
Granzyme B   3/4 (75)
TCR  βf1   5/5 (100)
TCR  γ PCR   4/8 (50)
SPTL: subcutaneous panniculitis-like T-cell lymphoma, EBV:
Epstein-Barr virus, TCR: T-cell receptor, PCR: Polymerase chain 
reaction.
primarily in the subcutaneous tissue. In five patients, a 
small minority of lymphocytes extended into the deep 
dermis, in a periadnexal pattern in three and in a 
perivascular pattern in two.
The subcutaneous lesions consisted of pleomorphic, 
small-to-medium-sized cells, plus a few diffuse large T 
cells containing hyperchromatic, irregularly contoured 
nuclei (Fig. 2).
All 14 patients showed evidence of rimming (i.e., 
individual fat cells rimmed by atypical lymphocytes). A 
variable admixture of karyorrhexis was present, as were 
macrophages filled with nuclear debris in the cytoplasm, 
generating the typical bean-bag appearance. Thirteen 
patients showed evidence of necrosis, with five showing 
angiocentric infiltration, but none showed angioinvasion 
or angiodestruction. Immunophenotype, EBV status, and TCR gamma gene 
rearrangement (Table 4)
In most patients, the neoplastic lymphocytes had a CD4−/ Subcutaneous Panniculitis-Like T-cell Lymphoma in Korea
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Table 5. Clinical comparison with previous studies
Korea (n=14)  China, 2009 (n=23)  Europe, 2008 (n=63)
M：F ratio 2.5：11 ：1.75 1：2
Mean age, y (range) 35.07 (7∼73) 32.3 (9∼72) 36 (9∼79)
Duration, (months)  21.2 (mean) Unknown  7 (median)
Extent of cutaneous Multiple: 12 (86) Multiple: 17 (77) Multiple: 49 (78)
 involvement, (%) Regional: 2 (14)  Solitary: 5 (23) Regional: 6 (9) 
Solitary: 0 (0) Solitary: 8 (13)
Presenting skin lesions 
  Ulceration, (%)     0 (0)    4 (18)  4 (6)
Distribution, (n) T(10)＞LE(9)＞UE(8)＞FACE(4) LE(17)＞T(13)＞UE(11)＞FACE(2) LE(45)＞UE(39)＞T(35)＞FACE(16)
Extracutaneous manifestations
  B symptoms, (%)  9/13 (69) Fever: 8 (36) 37 (59)
  HPS, (%)  2/14 (14)    0 (0) 11 (17)
  Splenomegaly, (%)  4/13 (31)    4 (18)  5 (8)
  LN involvement, (%)  5/13 (39)    0 (0)  5 (8)
Initial treatment
  Chemotherapy, (%)     10 (71)   14 (64) 31 (49)
  Immunosuppressive      3 (21) 24 (38)
   t h e r a p y ,  ( % )
  Radiotherapy, (%)     0 (0)  3 (5)
  Surgery, (%)      0 (0)    2 (9)  2 (3)
  ASCT, (%)     0 (0)
  No therapy, (%)     1 (8)  2 (3)
  Unknown, (%)     0 (0)  1 (2)
Result initial treatment
  CR     4 (29) 6/14 (43) 42 (67)
  PR     2 (14) 3/14 (21)  8 (13)
  SD     1 (7)  6 (10)
  PD     7 (50)  6 (10)
Status at last follow-up
  Alive and well, (%)     3 (21) 39 (62)
  Alive with disease, (%)     9 (64) 15 (24)
  Died of lymphoma, (%)     2 (14)    3 (14)   8 (13)
  Died of other cause, (%)     0 (0)    2 (9)  1 (2)
M: male, F: female, HPS: hemophagocytic syndrome, LN: lymph node, ASCT: autologous stem cell transplantation, CR: complete 
remission, PD: partial remission, SD: stable disease, PD: progressive disease.
CD8＋ phenotype, except for one patient with a CD4＋/ 
CD8− phenotype. All tumors assayed were negative for 
CD20, CD30 and CD56. The cytotoxic proteins TIA-1 and 
granzyme B were expressed in 9 of 9 and 3 of 4 patients, 
respectively (Fig. 3). All five patients tested were positive 
for betaF1, confirming their alpha/beta T-cell phenotype. 
ISH showed that all eight patients assayed were negative 
for EBV. Four of eight patients showed clonal 
rearrangements of the TCR gamma gene.
Treatment, follow-up, and survival analysis (Tables 1 
and 2)
Of the 14 patients, 6 were treated with cyclophospha-
mide, doxorubicin, vincristine, and prednisone (CHOP) 
chemotherapy, 4 with chemotherapy other than CHOP, 3 
with immunosuppressive therapy, and 1 with symptomatic 
therapy. Of the six patients receiving CHOP, two showed 
complete response (CR), one showed partial response 
(PR), and three showed progressive disease (PD). One 
patient died due to lymphoma after 4 months. Of the two 
patients achieving CR as initial response, one remained in 
CR at the time of follow-up. Of the five patients found to 
have disease during the follow-up, one patient with 
hemophagocytic syndrome (HPS) underwent autologous 
stem cell transplantation (ASCT) and radiotherapy.
Of the four patients receiving chemotherapy other than 
CHOP, one each had CR, PR, no response and PD. None 
attained complete remission during the follow-up period. 
After changing the chemotherapy regimen, one patient 
achieved CR during the follow-up.
Of the three patients treated initially with immunosuppre-
ssive agents (i.e., systemic steroids), including combina-
tions of prednisone and hydroxychloroquine, only one 
achieved CR, whereas two showed PD, with one of the 
latter receiving chemotherapy (vorinostat). In addition, 
one patient with HPS received symptomatic treatment (i.e., 
transfusion, nutritional supplements, and diuretics), but 
died after 4 months.DW Lee, et al
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Two patients underwent ASCT following chemotherapy. 
One patient was in CR, whereas the other had PD and 
was treated with radiotherapy.
At the end of the follow-up period, three patients had 
achieved CR and two patients had died. Survival analysis 
using the Kaplan-Meier method showed that the extent of 
skin involvement (localized vs multiple, p=0.290), the 
type of treatment (immunosuppressive therapy vs other, 
p=0.138), the presence of HPS (p=0.354), lymphadeno-
pathy (p=0.193), splenomegaly (p=0.217), angiocen-
tricity (p=0.170), the involvement of the dermis (p= 
0.153), and the positivity for TCR gamma gene rearrange-
ment were not significantly related to the patient survival.
DISCUSSION
The recent WHO-EORTC classification of primary cutane-
ous lymphomas
2 has restricted the category of SPTL to 
tumors expressing the TCR α β phenotype, placing those 
expressing the TCR γ δ  phenotype into a new provisional 
category of cutaneous γ δ T-cell lymphoma. There have 
been few studies of SPTL using this definition
4,5. We 
therefore sought to determine the primary clinical, 
histologic and immunophenotypical characteristics of 
patients with SPTL and compare them with those of 
patients included in previous studies (Table 5).
In contrast to the previously reported female predomi-
nance, we observed a male predominance in our popula-
tion. The mean patient age (35.1 years) was similar to that 
reported previously (i.e., 32.3 and 36 years)
4,5. The mean 
disease duration prior to diagnosis was 21.2 months in our 
study. Most patients presented with a deep-seated plaque 
or nodule, most commonly in the trunk, but also in the 
lower extremities, upper extremities, and face. In contrast 
to previous findings, none of our patients had solitary 
lesions or ulcerations. B symptoms and splenomegaly 
were more common than previously reported, whereas 
the incidence of hemophagocytic syndrome was similar 
(14%) to that of a European study (17%).
SPTL has been associated with autoimmune disorders, 
including systemic lupus erythematosus, juvenile rheuma-
toid arthritis, type 1 diabetes mellitus, Sjogren syndrome, 
and idiopathic thrombocytopenic purpura
4,6. The relation-
ship between SPTL and lupus erythematosus profundus 
(LEP) is unclear. Histopathologic criteria have been found 
useful in differentiating LEP from SPTL, suggesting that 
they represent distinct entities
7. Histopathologic criteria 
favoring the diagnosis of LEP include epidermal involve-
ment, mucin depositions, the presence of reactive 
germinal centers, clusters of B cells or considerable 
number of admixed plasma cells, and polyclonal TCRγ 
gene rearrangement. In contrast, several features of LEP 
and SPTL have been found to overlap, suggesting that 
these patients should be categorized as having “atypical 
lymphocytic lobular panniculitis”, distinct from both SPTL 
and LEP
8. In a large European cohort of 63 patients with 
SPTL
4, four patients were definitively diagnosed with LE 
and another four were initially misdiagnosed with lupus 
panniculitis. These findings indicate that features of SPTL 
and LEP may overlap in a small proportion of patients and 
that all patients with suspected SPTL should be screened 
for LE. In addition, SPTL may arise secondarily following 
long-standing LEP, suggesting that patients with LE, 
particularly those with LEP, should be monitored for 
development of SPTL
9. Of our 14 patients, 1 showed 
overlapping features of LEP and SPTL, including mild 
vacuolar changes at the dermo-epidermal junction and a 
few plasma cells in the subcutaneous tissue. However, the 
presence of cellular atypia and clonal TCR gamma gene 
rearrangements, as well as the clinical characteristics, 
favored the diagnosis of SPTL. This patient was treated 
with immunosuppressive therapy (prednisone＋HCQ). In 
contrast, none of our other patients showed any clinical, 
serologic or histopathologic abnormalities indicative of 
autoimmune disease.
TCR gene rearrangement was performed as an adjuvant 
diagnostic method in previously reported SPTL cases, with 
a different clonal detection rate, varying from 50% to 
80%
10,11. The presence of massive necrosis in the skin 
biopsy specimens may be a possible reason for cases with 
negative results
12. In this study, clonal rearrangement of 
the TCR gamma gene was detected in 4 of 8 tested patients 
(50%), which was consistent with previous reports. In the 
patients who did not show clonal TCR gamma gene 
rearrangment, the diagnosis of SPTL had finally been made 
by histopathologic findings and immunophenotype, 
including the positive staining for TCR-beta F1.
SPTL is usually treated with combination chemotherapy, 
most commonly anthracycline-based agents, such as 
CHOP or CHOP-like regimens
11. A recent European 
report
4, however, suggested that prednisolone or other 
immunosuppressive agents may provide benefits equi-
valent to those of either CHOP-like or aggressive regi-
mens, both in patients with primary tumors and those with 
relapsed disease.
We found that similar percentages of patients achieved CR 
following treatment with immunosuppressive (1 of 3 
patients) and CHOP (2 of 6 patients) regimens. Patients 
with relatively indolent or localized disease tend to be 
treated with immunosuppressive therapy, but responses 
are relatively short-lived, with subsequent progression 
after steroid doses are tapered. Additional studies of Subcutaneous Panniculitis-Like T-cell Lymphoma in Korea
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immunosuppressive therapy in patients with SPTL are 
required before conclusions can be drawn.
ASCT has shown impressive response rates after high-dose 
chemotherapy, with most patients achieving CR at a 
median follow-up of 14 months
13-16, although the condi-
tioning regimens in these previous studies varied. Two of 
our 14 patients underwent ASCT following chemotherapy; 
although one was in CR, the other showed evidence of 
tumor recurrence.
SPTL has generally been associated with favorable pro-
gnosis and protracted disease course, with 5-year survival 
rates  ＞80%
10,11,17. Of our 14 patients, 2 died due to 
disease progression at a mean 4 months after diagnosis. 
Both the presence of HPS and angioinvasion have been 
found to be significant indicators of poor prognosis. HPS 
is a multisystem illness characterized by fever, wasting, 
adenopathy, hepatosplenomegaly, pancytopenia, coagulo-
pathy, hyperferritinemia and hypertriglyceridemia, devel-
ops in about 20% of SPTL patients and is associated with a 
poor outcome, with a 5-year survival rate of 46%
4. Two of 
our 14 patients had HPS, but none had angioinvasion. We 
did not identify any prognostic factors significant for 
survival. The extent of skin involvement (localized vs 
multiple), the type of treatment (immunosuppressive 
therapy vs other), the presence of HPS, lymphadenopathy, 
splenomegaly, angiocentricity, involvement of dermis, 
and the positive TCR gamma gene rearrangement were 
not significant prognostic factors.
This study had limitations. The follow-up period was 
relatively short to estimate the 5-year survival rate. 
Second, the number of included patients was small. 
Therefore, additional studies including larger number of 
patients and with a longer follow-up period are needed.
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